Is rimonabant a safe and effective treatment for obesity?  

Oleh:

Aronne, Louis J

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Medical Progress vol. 34 no. 06 (Jun. 2007), page 266.

Ketersediaan

Perpustakaan FK Nomor Panggil: M36.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

BACKGROUND:To determine whether rimonabant is a safe and effective treatment for obesity. DESIGN: Randomized, controlled trials of rimonabant for the treatment of obesity were identified from the Cochrane Library, MEDLlNE, EM BASE, and the Latin American and Caribbean Health Sciences Literature (LILACS) databases. Searches were performed with a combination of keywords and there were no language restrictions. Eligible studies were those with a design that compared rimonabant with placebo and/or another intervention in participants aged ;;,18 years who were overweight or obese at enrolment. RESULTS: Four multicentre studies met the inclusion criteria: Rimonabant in Obesity (RIO)-North America, RIO-Europe, RIO-Lipids, and RIO-Diabetes. The selected studies involved 6,625 participants with a BMI >27 kg/m' before enrolment. In addition to caloric restriction (600 kcal daily deficit), participants were randomly allocated to receive 20 mg rimonabant, 5 mg rimonabant or placebo. Intervention was for 24 months in RIO-North America, and for 12 months in the other studies. Compared with placebo, 20 mg rimonabant and 5 mg rimonabant resulted in mean weight reductions of 4.9 kg and 1.3 kg, respectively. In addition, treatment with 20 mg rimonabant and 5 mg rimonabant resulted in a mean waist circumference reduction of 3.8 cm and 1.2 cm, respectively. Compared with placebo, treatment with 20 mg rimonabant resulted in a 0.2 mmoliL mean reduction in triglyceride levels and a 0.1 mmol/L mean increase in high-density lipoprotein cholesterol (HDL-C) levels. Both systolic and diastolic blood pressures 2 mmHg and 1 mmHg, respectively).The effects of 5 mg rimonabant on lipid profiles and blood pressure were not statistically significant. Despite the observed benefits, 20 mg rimonabant was associated with an increased incidence of both general (p;0.005) and serious (p;0.03) adverse effects when compared with 5 mg rimonabant or placebo. Discontinuation of the study medication because of adverse effects was also more common with 20 mg rimonabant than with 5 mg rimonabant or placebo. CONCLUSION: A dose of 20 mg rimonabant improved weight measurements as well as risk factors associated with obesity. However, further studies are warranted to assess rimonabant comprehensively as a treatment for obesity.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali